Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Orismilast Formulations in Healthy Subjects
NCT03812198Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Jan 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of orismilast in psoriasis and atopic dermatitis (AD), sponsored by LEO Pharma. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity at Day 17, Maximum Plasma Concentration at Day 17 and 2 more. Started Jan 2019; status: completed.
02
Drugs
orismilast
03
Conditions
psoriasisatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03812198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812198.